145 results on '"Currier, Judith S"'
Search Results
2. Prevalence and Factors Associated With Antigen Test Positivity Following SARS-CoV-2 Infection Among Health Care Workers in Los Angeles.
- Author
-
Adamson, Paul C, Currier, Judith S, Uslan, Daniel Z, and Garner, Omai B
- Subjects
- *
MEDICAL personnel , *SARS-CoV-2 , *ANTIGEN analysis , *CORONAVIRUS diseases , *LABOR demand - Abstract
Surges of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among health care workers (HCWs) have led to critical staffing shortages. From January 4 to February 4, 2022, we implemented a return-to-work antigen testing program for HCWs, and 870 HCWs participated. Antigen test positivity was 60.5% for those ≤5 days from symptom onset or positive polymerase chain reaction (PCR), and 47.4% were positive at day 7. Antigen positivity was associated with receiving a booster vaccination and being ≤6 days from symptom onset or PCR test, but not age or a symptomatic infection. Rapid antigen testing can be a useful tool to guide return-to-work and isolation precautions for HCWs following infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial.
- Author
-
Zanni, Markella V, Currier, Judith S, Kantor, Amy, Smeaton, Laura, Rivard, Corinne, Taron, Jana, Burdo, Tricia H, Badal-Faesen, Sharlaa, Lalloo, Umesh G, Pinto, Jorge A, Samaneka, Wadzanai, Valencia, Javier, Klingman, Karin, Allston-Smith, Beverly, Cooper-Arnold, Katharine, Desvigne-Nickens, Patrice, Lu, Michael T, Fitch, Kathleen V, Hoffman, Udo, and Grinspoon, Steven K
- Subjects
- *
HIV , *CLINICAL trial registries , *ANTI-Mullerian hormone , *OVARIAN reserve , *MIDDLE age - Abstract
Background: Reproductive aging may contribute to cardiometabolic comorbid conditions. We integrated data on gynecologic history with levels of an ovarian reserve marker (anti-müllerian hormone [AMH)] to interrogate reproductive aging patterns and associated factors among a subset of cisgender women with human immunodeficiency virus (WWH) enrolled in the REPRIEVE trial.Methods: A total of 1449 WWH were classified as premenopausal (n = 482) (menses within 12 months; AMH level ≥20 pg/mL; group 1), premenopausal with reduced ovarian reserve (n = 224) (menses within 12 months; AMH <20 pg/mL; group 2), or postmenopausal (n = 743) (no menses within12 months; AMH <20 pg/mL; group 3). Proportional odds models, adjusted for chronologic age, were used to investigate associations of cardiometabolic and demographic parameters with reproductive aging milestones (AMH <20 pg/mL or >12 months of amenorrhea). Excluding WWH with surgical menopause, age at final menstrual period was summarized for postmenopausal WWH (group 3) and estimated among all WWH (groups 1-3) using an accelerated failure-time model.Results: Cardiometabolic and demographic parameters associated with advanced reproductive age (controlling for chronologic age) included waist circumference (>88 vs ≤88 cm) (odds ratio [OR], 1.38; 95% confidence interval, 1.06-1.80; P = .02), hemoglobin (≥12 vs <12 g/dL) (2.32; 1.71-3.14; P < .01), and region of residence (sub-Saharan Africa [1.50; 1.07-2.11; P = .02] and Latin America and the Caribbean [1.59; 1.08-2.33; P = .02], as compared with World Health Organization Global Burden of Disease high-income regions). The median age (Q1, Q3) at the final menstrual period was 48 (45, 51) years when described among postmenopausal WWH, and either 49 (46, 52) or 50 (47, 53) years when estimated among all WWH, depending on censoring strategy.Conclusions: Among WWH in the REPRIEVE trial, more advanced reproductive age is associated with metabolic dysregulation and region of residence. Additional research on age at menopause among WWH is needed.Clinical Trials Registration: NCT0234429. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
4. The Role of Inflammation in HIV-Associated Atherosclerosis-One Size May Not Fit All.
- Author
-
Currier, Judith S and Hsue, Priscilla Y
- Subjects
- *
INFLAMMATION , *SIZE , *ANTI-inflammatory agents , *ATHEROSCLEROSIS , *CORONARY disease , *HIV , *HIV infections , *INTERLEUKINS - Published
- 2020
- Full Text
- View/download PDF
5. Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3.
- Author
-
Currier, Judith S., Britto, Paula, Hoffman, Risa M., Brummel, Sean, Masheto, Gaerolwe, Joao, Esau, Santos, Breno, Aurpibul, Linda, Losso, Marcelo, Pierre, Marie F., Weinberg, Adriana, Gnanashanmugam, Devasena, Chakhtoura, Nahida, Klingman, Karin, Browning, Renee, Coletti, Anne, Mofenson, Lynne, Shapiro, David, Pilotto, Jose, and null, null
- Subjects
- *
ANTIRETROVIRAL agents , *CD antigens , *PREVENTIVE medicine , *LOPINAVIR-ritonavir , *RANDOMIZED controlled trials - Abstract
Background: Health benefits of postpartum antiretroviral therapy (ART) for human immunodeficiency virus (HIV) positive women with high CD4+ T-counts have not been assessed in randomized trials. Methods: Asymptomatic, HIV-positive, non-breastfeeding women with pre-ART CD4+ T-cell counts ≥ 400 cells/mm3 started on ART during pregnancy were randomized up to 42 days after delivery to continue or discontinue ART. Lopinavir/ritonavir plus tenofovir/emtricitabine was the preferred ART regimen. The sample size was selected to provide 88% power to detect a 50% reduction from an annualized primary event rate of 2.07%. A post-hoc analysis evaluated HIV/AIDS-related and World Health Organization (WHO) Stage 2 and 3 events. All analyses were intent to treat. Results: 1652 women from 52 sites in Argentina, Botswana, Brazil, China, Haiti, Peru, Thailand and the US were enrolled (1/2010-11/2014). Median age was 28 years and major racial categories were Black African (28%), Asian (25%) White (15%). Median entry CD4 count was 696 cells/mm3 (IQR 575–869), median ART exposure prior to delivery was 19 weeks (IQR 13–24) and 94% had entry HIV-1 RNA < 1000 copies/ml. After a median follow-up of 2.3 years, the primary composite endpoint rate was significantly lower than expected, and not significantly different between arms (continue arm 0.21 /100 person years(py); discontinue 0.31/100 py, Hazard ratio (HR) 0.68, 95% CI: 0.19, 2.40). WHO Stage 2 and 3 events were significantly reduced with continued ART (2.08/100 py vs. 4.36/100 py in the discontinue arm; HR 0.48, 95%CI: 0.33, 0.70). Toxicity rates did not differ significantly between arms. Among women randomized to continue ART, 189/827 (23%) had virologic failure; of the 155 with resistance testing, 103 (66%) failed without resistance to their current regimen, suggesting non-adherence. Conclusions: Overall, serious clinical events were rare among young HIV-positive post-partum women with high CD4 cell counts. Continued ART was safe and was associated with a halving of the rate of WHO 2/3 conditions. Virologic failure rates were high, underscoring the urgent need to improve adherence in this population. Trial registration: ClinicalTrials.gov [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Metabolic disease in HIV infection.
- Author
-
Lake, Jordan E and Currier, Judith S
- Subjects
- *
METABOLIC disorders , *ANTIRETROVIRAL agents , *HIV-positive persons , *HIV infection risk factors , *ADIPOSE tissue diseases , *INFLAMMATION , *HOMEOSTASIS , *THERAPEUTICS , *HIV infections - Abstract
Summary: The treatment of metabolic disease is becoming an increasingly important component of the long-term management of patients with well controlled HIV on antiretroviral therapy (ART). Metabolic diseases probably develop at the intersection of traditional risk factors (such as obesity, tobacco use, and genetic predisposition) and HIV-specific and ART-specific contributors (including chronic inflammation and immune activation). This Review discusses present knowledge on adipose tissue dysfunction, insulin–glucose homoeostasis, lipid disturbances, and cardiovascular disease risk in people with HIV on ART. Although new antiretroviral drugs are believed to induce fewer short-term metabolic perturbations than do older drugs, the long-term effects of these drugs are not fully understood. Additionally, patients remain at increased risk of cardiovascular disease and other metabolic comorbidities. Research and treatment should focus on selection of ART that is both virologically effective and has minimum metabolic effects, minimisation of traditional risk factors for metabolic disease, and development of novel therapies to treat metabolic disease in patients with HIV, including use of anti-inflammatory and immunomodulatory drugs. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
7. Sex Differences in Lopinavir and Ritonavir Pharmacokinetics Among HIV-Infected Women and Men.
- Author
-
Umeh, Obi C., Currier, Judith S., Park, Jeong-Gun, Cramer, Yoninah, Hermes, Ashwaq E., and Fletcher, Courtney V.
- Subjects
- *
ANALYSIS of covariance , *ANALYSIS of variance , *BIOAVAILABILITY , *BIOLOGICAL assay , *BLOOD testing , *COMBINATION drug therapy , *CONFIDENCE intervals , *PHARMACEUTICAL gels , *HIGH performance liquid chromatography , *HIV infections , *HIV-positive persons , *LONGITUDINAL method , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *SEX distribution , *STATISTICS , *DRUG tablets , *DATA analysis , *ANTIRETROVIRAL agents , *LOPINAVIR-ritonavir , *TENOFOVIR - Abstract
The authors compared the pharmacokinetics of lopinavir (LPV) and ritonavir (RTV) between women and men. This 2-step, multicenter, pharmacokinetic study enrolled human immunodeficiency virus (HIV)–infected adults on lopinavir/ritonavir (LPV/r) capsules (400/100 mg bid) plus 1 or more nucleoside reverse transcriptase inhibitors. All participants underwent 12-hour pharmacokinetic sampling. The pharmacokinetic sampling was repeated in participants receiving the LPV/r tablet formulation. Step 1 enrolled 37 women and 40 men; step 2 included 42 participants from step 1 plus 35 new participants (39 women and 38 men). LPV pharmacokinetics in women and men were not significantly different with either formulation. Women had significantly higher median RTV AUC0-12 h with both the soft-gel capsule (SGC) and tablet formulations (SGC: 5395 vs 4119 ng·h/mL, P = .026; tablet: 5310 vs 3941 ng·h/mL, P = .012), higher median Cmax (SGC: 802 vs 635 ng/mL, P = .032; tablet: 773 vs 570 ng/mL, P = .006), and lower median CL/F (SGC: 18.54 vs 24.31 L/h, P = .026; tablet: 18.83 vs 25.37 L/h, P = .012). RTV CL/F was slower in women after weight adjustment with both formulations. The pharmacokinetics of LPV in the SGC and tablet formulations are comparable in HIV-infected patients. Women had higher RTV AUC0-12 h and lower CL/F with both formulations. The mechanism of the sex difference in RTV CL/F warrants elucidation. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
8. Effects of Darunavir/Ritonavir-Based Therapy on Metabolic and Anthropometric Parameters in Women and Men Over 48 Weeks.
- Author
-
Currier, Judith S., Martorell, Claudia, Osiyemi, Olayemi, Yin, Michael T., Ryan, Robert, De La Rosa, Guy, and Mrus, Joseph
- Subjects
- *
BLOOD sugar analysis , *PATIENTS , *AGE distribution , *ANALYSIS of variance , *ANTIVIRAL agents , *ATTITUDE (Psychology) , *BLOOD testing , *CHI-squared test , *CLINICAL trials , *HIV infections , *HIV-positive persons , *INSULIN , *LIPIDS , *METABOLISM , *RESEARCH funding , *STATISTICAL sampling , *SELF-evaluation , *SEX distribution , *STATISTICS , *T-test (Statistics) , *TRIGLYCERIDES , *WEIGHT gain , *DATA analysis , *PROTEASE inhibitors , *SECONDARY analysis , *BODY mass index , *DARUNAVIR - Abstract
Gender-based differences in lipids have been noted in antiretroviral clinical trials. We present the metabolic and anthropometric data from the GRACE (Gender, Race And Clinical Experience) study by gender. Treatment-experienced adults received darunavir/ritonavir (DRV/r) 600/100 mg twice daily, plus a background regimen, over 48 weeks. Fasting blood samples were obtained for lipid, glucose, and insulin measurements at baseline and at weeks 24 and 48/early discontinuation. Anthropometric measurements were taken at baseline and at weeks 12, 24, and 48/discontinuation. The Assessment of Body Change and Distress questionnaire was administered at baseline and regular intervals. Descriptive statistics as well as comparisons using a Wilcoxon rank-sum test are reported. Four hundred twenty-nine patients (women, n=287; men, n=142) enrolled in GRACE; 94 women (32.8%) and 33 men (23.2%) discontinued the trial. Median changes in triglycerides from baseline to week 48 were higher in men (25 mg/dL versus 8 mg/dL; p=0.006); the mean change in triglycerides was higher in men than in women in all racial subgroups. Other lipid and glucose level changes were similar between genders. Anthropometric parameters increased for both genders, with larger increases in women. Patients' perceptions of body changes concurred with physical measurements. The proportion of women who were 'satisfied' or 'very satisfied' with their bodies increased from 45.2% to 57.8% from baseline to week 48 ( p=0.005), while the proportion of men who were 'satisfied' or 'very satisfied' with their bodies increased from 56.3% to 61.5% from baseline to week 48 ( p=0.317). DRV/r-based therapy was associated with small to moderate changes in metabolic parameters, and few between-gender differences were observed. Levels of self-reported, body-related distress improved for women and men over 48 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Postexposure Prophylaxis for HIV Infection.
- Author
-
Landovitz, Raphael J. and Currier, Judith S.
- Subjects
- *
DENTAL prophylaxis , *THERAPEUTICS , *HIV infections , *OUTPATIENT medical care , *ANAL sex , *ANTIVIRAL agents - Abstract
The article discusses the use of postexposure prophylaxis against human immunodeficiency virus (HIV) infection in the U.S. as of October 2009. It says that a 24-year-old man reported that he had receptive anal intercourse with an anonymous male partner 36 hours before he went into an outpatient clinic. According to the author, the history of the use of postexposure prophylaxis as a treatment for this chronic infection can be traced back to the early parts of the 1990s, which was the time when antiviral treatment was limited. Details of assessing the need for postexposure prophylaxis and the prevalence of HIV infection in the country are also discussed.
- Published
- 2009
- Full Text
- View/download PDF
10. In Memoriam: Scott M. Hammer, MD.
- Author
-
El‐Sadr, Wafaa M., Currier, Judith S., and Corey, Larry
- Subjects
- *
EMERGING infectious diseases , *HAMMERS , *HIV infections - Abstract
Scott's career began as the HIV epidemic in the United States unfolded and, in many ways, the epidemic shaped his career, which was true for many infectious disease specialists of that era. The Infectious Disease community lost a giant, Dr. Scott M. Hammer, on 17 November 2021. When the major advances achieved by Scott and others allowed HIV to be transformed into a chronic and manageable condition, he turned his attention to the challenge of HIV prevention. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
11. Monthly Injectable Antiretroviral Therapy - Version 1.0 of a New Treatment Approach.
- Author
-
Currier, Judith S.
- Abstract
The article offers information on the Antiretroviral Therapy as Long Acting Suppression (ATLAS) and First Long-Acting Injectable Regimen (FLAIR) for the treatment of human immunodeficiency virus (HIV). It further discusses availability of several single-tablet multidrug treatment regimens that effectively control the replication of HIV type 1 (HIV-1); Combination antiretroviral therapy (ART), one of the most important advances in medicine; and intramuscular injections of drugs every 4 weeks.
- Published
- 2020
- Full Text
- View/download PDF
12. Coronary Heart Disease in HIV-Infected Individuals.
- Author
-
Currier, Judith S., Taylor, Anne, Boyd, Felicity, Dezii, Christopher M., Kawabata, Hugh, Burtcel, Beth, Jen-Fue Maa, and Hodder, Sally
- Subjects
- *
CORONARY disease , *HIV-positive persons , *ANTIRETROVIRAL agents - Abstract
Compares the incidence of and relative risk for coronary heart disease (CHD) in HIV-infected individuals. Use of log linear regression analyses; Association of exposure to antiretroviral therapy and CHD incidence; Distribution of CHD diagnoses.
- Published
- 2003
- Full Text
- View/download PDF
13. Cardiovascular Risk Associated With HIV Therapy.
- Author
-
Currier, Judith S.
- Subjects
- *
CARDIOVASCULAR diseases , *THERAPEUTICS , *HIV infections - Abstract
Investigates the cardiovascular risk associated with HIV therapy. Use of highly active antiretroviral therapy in treating patients with HIV; Assessment of dyslipidemia in HIV-infected individuals; Types of cardiovascular risk factors.
- Published
- 2002
- Full Text
- View/download PDF
14. A Randomized Study of the Utility of Human Immunodeficiency Virus RNA Measurement for the Management of Antiretroviral Therapy.
- Author
-
Haubrich, Richard H., Currier, Judith S., Forthal, Donald N., Beall, Gildon, Kemper, Carol A., Johnson, Debra, Dube, Michael P., Hwang, Jimmy, Leedom, John M., Tilles, Jeremiah, and McCutchan, J. Allen
- Subjects
- *
HIV , *RETROVIRUS disease treatment , *HIV-positive persons - Abstract
To compare frequent measurement with infrequent measurement of human immunodeficiency virus (HIV) RNA levels in the management of antiretroviral therapy, we conducted a clinical strategy study of 206 HIV-infected patients who had <500 CD4 cells/mm[sup3]. Patients were randomized (1.5:1) to undergo frequent monitoring (at baseline and every 2 months) or infrequent monitoring (at baseline and twice yearly), with CD4 cell counts determined every 2 months. Patients received unrestricted antiretroviral therapy. In the primary analysis (at month 6), the frequent group had a mean HIV RNA reduction (&plusmin standard deviation) of 0.93 &plusmin 0.79 log[sub10] copies/mL, versus log10 copies/mL for the infrequent group (P=.0002). A trend (P =.1) toward improved survival was seen in the frequent group. Given this iproved virological response, more frequent HIV RNA measurement than is recommended in published guidelines (every 3--4 months) may be appropriate. [ABSTRACT FROM AUTHOR]
- Published
- 2001
15. Impact of Prophylaxis for Mycobacterium avium Complex on Bacterial Infections in Patients with Advanced Human Immunodeficiency Virus Disease.
- Author
-
Currier, Judith S., Williams, Paige, Feinberg, Judith, Becker, Simone, Owens, Susan, Fichtenbaum, Carl, and Benson, Constance
- Subjects
- *
BACTERIAL disease risk factors , *HIV-positive persons , *AMBULATORY patient groups , *HEALTH - Abstract
Presents a study which evaluated potential risk factors for the development of serious bacterial infections among ambulatory patients with HIV disease. Patients and methods; Results and discussion.
- Published
- 2001
16. Discontinuation of Mycobacterium aviumComplex Prophylaxis in Patients with Antiretroviral Therapy-Induced Increases in CD4 1 Cell Count.
- Author
-
Currier, Judith S., Williams, Paige L., Koletar, Susan L., Cohn, Susan E., Murphy, Robert L., Heald, Alison E., Hafner, Richard, Bassily, Ehab L., Lederman, Howard M., Knirsch, Charles, Benson, Constance A., Valdez, Hernan, Aberg, Judith A., and McCutchan, J. Allen
- Subjects
- *
MYCOBACTERIUM avium , *PLACEBOS , *HIV-positive persons - Abstract
Compares the rate of Mycobacterium avium complex infection in patients with increased CD4[sup+] cell counts who receive azithromycin and placebo. Involvement of HIV infected patients with low cell count; Measurement of Mycobacterium cultures, CD4[sup+] cell count and clinical evaluations; Localization of the Mycobacterium avium to the vertebral spine; Safety of withdrawal of prophylaxis against M. avium complex.
- Published
- 2000
- Full Text
- View/download PDF
17. Discontinuing Prophylaxis for Opportunistic Infection: Guiding Principles.
- Author
-
Currier, Judith S.
- Subjects
- *
OPPORTUNISTIC infections , *DECISION making in clinical medicine , *DRUG therapy - Abstract
Determines whether subjects who respond to antiretroviral therapy need to continue chemoprophylaxis for opportunistic infection (OI). Reduced risk of OI among recipients of potent combination antiretroviral therapy; Assessment of the risk of developing the specific OI; Consequences of the infection; Short- and long-term toxicity of the agent used for prophylaxis.
- Published
- 2000
- Full Text
- View/download PDF
18. Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
- Author
-
Choudhary, Manish C, Deo, Rinki, Evering, Teresa H, Chew, Kara W, Giganti, Mark J, Moser, Carlee, Ritz, Justin, Regan, James, Flynn, James P, Crain, Charles R, Wohl, David Alain, Currier, Judith S, Eron, Joseph J, Margolis, David, Zhu, Qing, Zhon, Lijie, Ya, Li, Greninger, Alexander L, Hughes, Michael D, and Smith, Davey
- Subjects
- *
SARS-CoV-2 , *VIRAL load , *NUCLEOTIDE sequencing , *TREATMENT effectiveness , *DISEASE progression - Abstract
Background Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether combination mAbs offer a benefit over single-active mAb treatment. Amubarvimab and romlusevimab significantly reduced the risk of hospitalizations or death in the ACTIV-2/A5401 trial. Certain SARS-CoV-2 variants are intrinsically resistant against romlusevimab, leading to only single-active mAb therapy with amubarvimab in these variants. We evaluated virologic outcomes in individuals treated with single- versus dual-active mAbs. Methods Participants were nonhospitalized adults at higher risk of clinical progression randomized to amubarvimab plus romlusevimab or placebo. Quantitative SARS-CoV-2 RNA levels and targeted S-gene next-generation sequencing was performed on anterior nasal samples. We compared viral load kinetics and resistance emergence between individuals treated with effective single- versus dual-active mAbs depending on the infecting variant. Results Study participants receiving single- or dual-active mAbs had similar demographics, baseline nasal viral load, symptom score, and symptom duration. Compared with single-active mAb treatment, treatment with dual-active mAbs led to faster viral load decline at study days 3 (P <.001) and 7 (P <.01). Treatment-emergent resistance mutations were more likely to be detected after amubarvimab plus romlusevimab treatment than with placebo (2.6% vs 0%; P <.001) and were more frequently detected in the setting of single-active compared with dual-active mAb treatment (7.3% vs 1.1%; P <.01). Single-active and dual-active mAb treatment resulted in similar decrease in rates of hospitalizations or death. Conclusions Compared with single-active mAb therapy, dual-active mAbs led to similar clinical outcomes but significantly faster viral load decline and a lower risk of emergent resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.
- Author
-
Cyktor, Joshua C., Yeh, Eunice, Ribaudo, Heather, Hoeth, Dianna, Naqvi, Asma, Bell, Tanvir, Ridker, Paul M., Fichtenbaum, Carl, Daar, Eric S., Havlir, Diane, Tawakol, Ahmed, Lederman, Michael M., Stein, James H., Deeks, Steven G., Currier, Judith S., Hsue, Priscilla Y., and Mellors, John W.
- Abstract
Background: People with HIV-1 often have chronic inflammation leading to severe non-AIDS morbidity and mortality. The AIDS Clinical Trials Group Study A5314 sought to lower inflammation with low-dose methotrexate (LDMTX). The primary study outcomes were reported previously but here we present the impact of LDMTX on multiple measures of HIV-1 persistence. Methods: A5314 was a phase 2 randomized, double-blind, multicenter trial in 176 adult people with HIV-1 on virally suppressive antiretroviral therapy. LDMTX (5-15 mg/wk) was administered for 24 weeks with an additional 12 weeks of participant follow-up. The current analyses of HIV-1 persistence were restricted to 60 participants (30 LDMTX and 30 placebo) randomly selected from the total population. Plasma HIV-1 RNA, total HIV-1 DNA, and cell-associated HIV-1 RNA (CA HIV-1 RNA) were measured by sensitive quantitative PCR assays. Results: LDMTX treatment had no significant effect on sensitive measures of plasma HIV-1 RNA, HIV-1 DNA, CA HIV-1 RNA, or CA HIV-1 RNA/DNA ratio at any time point or from baseline to week 24. As observed in the main study, absolute peripheral CD4+ and CD8+ T-cell numbers decreased from baseline to week 24 among the 30 participants receiving LDMTX compared with placebo (median decrease of 231.5 CD4+ T cells/mL, 283.5 CD8+ T cells/mL). Conclusions: LDMTX had no significant effect on any measure of HIV-1 persistence in plasma or peripheral blood mononuclear cells. Further studies are needed to determine whether other immunosuppressive and/or immunoreductive interventions are safe and capable of affecting HIV-1 persistence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
20. Willingness to trade-off years of life for an HIV cure – an experimental exploration of affective forecasting.
- Author
-
Fridman, Ilona, Eyal, Nir, Scherr, Karen A., Currier, Judith S., Freedberg, Kenneth A., Halpern, Scott D., Kuritzkes, Daniel R., Magalhaes, Monica, Pollak, Kathryn I., and Ubel, Peter A.
- Subjects
- *
HEALTH attitudes , *RESEARCH funding , *LIFE expectancy , *STATISTICAL sampling , *QUESTIONNAIRES , *HIV infections , *DECISION making in clinical medicine , *RANDOMIZED controlled trials , *MULTIVARIATE analysis , *DESCRIPTIVE statistics , *QUALITY of life , *ANALYSIS of variance , *ANTI-HIV agents , *FORECASTING - Abstract
Background: In the US, 1.2 million people live with HIV (PWH). Despite having near-normal life expectancies due to antiretroviral therapy (ART), many PWH seek an HIV cure, even if it means risking their lives. This willingness to take risks for a cure raises questions about "affective forecasting biases," where people tend to overestimate the positive impact of future events on their well-being. We conducted a study to test two interventions to mitigate affective forecasting in the decisions of PWH about taking HIV cure medication. Methods: We recruited PWH to complete a 30-minute survey about their current quality of life (QoL) and the QoL they anticipate after being cured of HIV, and assigned them to either no additional intervention, to one of two interventions intended to reduce affective forecasting bias, or to both interventions: (1) a defocusing intervention designed to broaden the number of life domains people consider when imagining life changes associated with new circumstances (e.g. HIV cure); and (2) an adaptation intervention to help them gauge fading of strong emotions over time. The study design included a 2 × 2 design: defocusing (yes/no) x adaptation (yes/no) intervention. We assessed PWH's willingness to take hypothetical HIV sterilizing cure medication using the Time Trade-Off (TTO) and their quality of life predictions with WHOQOL-HIV. Results: 296 PWH participated. Counter to what we had hypothesized, neither intervention significantly reduced PWH's willingness to trade time for a cure. Instead, the defocusing intervention increased their willingness to trade time (IRR 1.77, p = 0.03). Exploratory analysis revealed that PWH with lower current quality of life who received the defocusing intervention were more willing to trade time for a cure. Conclusion: These negative findings suggest that either these biases are difficult to overcome in the settings of HIV curative medication or other factors beyond affective forecasting biases influence willingness to participate in HIV curative studies, such as respondents' current quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Alternative regimens for the prophylaxis of Mycobacterium avium complex in acquired immune...
- Author
-
Currier, Judith S. and McCutchan, J. Allen
- Subjects
- *
MYCOBACTERIUM avium , *AIDS patients , *THERAPEUTICS - Abstract
Focuses on rifabutin, clarithromycin and azithromycin and their use in the treatment of disseminated Mycobacterium avium complex (MAC) infections in acquired immune deficiency (AIDS) patients in placebo-controlled trials. Comparison of these drugs; Reference to a summary of the status of rifabutin and macrolides for MAC prophylaxis; Statistical data.
- Published
- 1997
- Full Text
- View/download PDF
22. Opportunistic Infections in the Age of Highly Active Antiretroviral Therapy.
- Author
-
Currier, Judith S.
- Subjects
- *
ANTIRHEUMATIC agents , *HIV , *OPPORTUNISTIC infections - Abstract
Focuses on the impact of antiretroviral therapies on opportunistic infections (OI), with reference to patients with human immunodeficiency virus (HIV). Identification of Mycobacterium avium as one of the easiest diseases contracted by HIV patients; Details on the results of the Ritonavir Placebo Study done on OIs; Reference to a reduction in OI cases; In-depth look at the impact of OIs on HIV replication.
- Published
- 1998
- Full Text
- View/download PDF
23. HIV and Atherosclerosis: Moving From Associations to Mechanisms and Interventions.
- Author
-
Currier, Judith S. and Stein, James H.
- Subjects
- *
HIV infections , *THERAPEUTICS , *ATHEROSCLEROSIS risk factors , *ANGIOGRAPHY , *COMPUTED tomography , *REGULATION of blood pressure - Abstract
The authors focus on a study by W.S. Post and colleagues on the risk of atherosclerosis in the patients treated for HIV infections, appeared in the April 1, 2014 issue of the journal. Topics include support of the study to earlier HIV-related studies, use of cardiac computed tomography (CT) for measuring coronary artery calcium (CAC), and coronary CT angiography for assessing plaque extent. Also discussed is a need of addressing blood pressure control for effective treatment of HIV infections.
- Published
- 2014
- Full Text
- View/download PDF
24. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
- Author
-
Phan, Tin, Zitzmann, Carolin, Chew, Kara W., Smith, Davey M., Daar, Eric S., Wohl, David A., Eron, Joseph J., Currier, Judith S., Hughes, Michael D., Choudhary, Manish C., Deo, Rinki, Li, Jonathan Z., Ribeiro, Ruy M., Ke, Ruian, and Perelson, Alan S.
- Subjects
- *
MONOCLONAL antibodies , *SARS-CoV-2 , *COVID-19 pandemic , *VIRUS diseases , *COVID-19 treatment , *VIRAL load - Abstract
To mitigate the loss of lives during the COVID-19 pandemic, emergency use authorization was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment of mild-to-moderate COVID-19 in patients with a high risk of progressing to severe disease. Monoclonal antibodies used to treat SARS-CoV-2 target the spike protein of the virus and block its ability to enter and infect target cells. Monoclonal antibody therapy can thus accelerate the decline in viral load and lower hospitalization rates among high-risk patients with variants susceptible to mAb therapy. However, viral resistance has been observed, in some cases leading to a transient viral rebound that can be as large as 3–4 orders of magnitude. As mAbs represent a proven treatment choice for SARS-CoV-2 and other viral infections, evaluation of treatment-emergent mAb resistance can help uncover underlying pathobiology of SARS-CoV-2 infection and may also help in the development of the next generation of mAb therapies. Although resistance can be expected, the large rebounds observed are much more difficult to explain. We hypothesize replenishment of target cells is necessary to generate the high transient viral rebound. Thus, we formulated two models with different mechanisms for target cell replenishment (homeostatic proliferation and return from an innate immune response antiviral state) and fit them to data from persons with SARS-CoV-2 treated with a mAb. We showed that both models can explain the emergence of resistant virus associated with high transient viral rebounds. We found that variations in the target cell supply rate and adaptive immunity parameters have a strong impact on the magnitude or observability of the viral rebound associated with the emergence of resistant virus. Both variations in target cell supply rate and adaptive immunity parameters may explain why only some individuals develop observable transient resistant viral rebound. Our study highlights the conditions that can lead to resistance and subsequent viral rebound in mAb treatments during acute infection. Author summary: Monoclonal antibodies have been used as a treatment for SARS-CoV-2. However, viral evolution and development of variants has compromised the use of all currently authorized monoclonal antibodies for SARS-CoV-2. In some individuals treated with one such monoclonal antibody, bamlanivimab, transient nasal viral rebounds of 3–4 logs associated with resistant viral strains occur. To better understand the mechanisms underlying resistance emergence with high viral load rebounds, we developed two different models that incorporate drug sensitive and drug resistant virus as well as target cell replenishment and fit them to data. The models accurately capture the observed viral dynamics as well as the proportion of resistant virus for each studied individual with little variation in model parameters. In the models with best-fit parameters, bamlanivimab selects for resistance mutants that can expand to high levels due to target cell replenishment. The ultimate clearance of virus however depends on the development of adaptive immunity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics.
- Author
-
LaVange, Lisa, Adam, Stacey J., Currier, Judith S., Higgs, Elizabeth S., Reineck, Lora A., Hughes, Eric A., Read, Sarah W., and ACTIV Therapeutics-Clinical Working Group
- Subjects
- *
COVID-19 , *COVID-19 treatment , *THERAPEUTICS , *PUBLIC-private sector cooperation , *VACCINES - Abstract
Working in an unprecedented time frame, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership developed and launched 9 master protocols between 14 April 2020 and 31 May 2021 to allow for the coordinated and efficient evaluation of multiple investigational therapeutic agents for COVID-19. The ACTIV master protocols were designed with a portfolio approach to serve the following patient populations with COVID-19: mild to moderately ill outpatients, moderately ill inpatients, and critically ill inpatients. To facilitate the execution of these studies and minimize start-up time, ACTIV selected several existing networks to launch the master protocols. The master protocols were also designed to test several agent classes prioritized by ACTIV that covered the spectrum of the disease pathophysiology. Each protocol, either adaptive or pragmatic, was designed to efficiently select those treatments that provide benefit to patients while rapidly eliminating those that were either ineffective or unsafe. The ACTIV Therapeutics-Clinical Working Group members describe the process by which these master protocols were designed, developed, and launched. Lessons learned that may be useful in meeting the challenges of a future pandemic are also described. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Immune Biomarkers in the Prediction of Future Myocardial Infarctions in People With Human Immunodeficiency Virus.
- Author
-
Trevillyan, Janine M, Moser, Carlee, Currier, Judith S, and Sallam, Tamer
- Subjects
- *
BIOMARKERS , *C-reactive protein , *CARDIOVASCULAR diseases risk factors , *HIV-positive persons , *MYOCARDIAL infarction , *RETROSPECTIVE studies , *CASE-control method , *LIPOPOLYSACCHARIDES - Abstract
In a retrospective case control analysis, following adjustments for high-sensitivity C-reactive protein (hsCRP), traditional cardiovascular risk factors, and the CD4/CD8 T-cell ratio, higher lipopolysaccharide-binding protein (LBP) was associated with future myocardial infarctions in hsCRP human immunodeficiency virus (HIV). LBP may be a marker of cardiovascular risk with utility in HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort.
- Author
-
Foldyna, Borek, Mayrhofer, Thomas, Zanni, Markella V, Lyass, Asya, Barve, Radhika, Karady, Julia, McCallum, Sara, Burdo, Tricia H, Fitch, Kathleen V, Paradis, Kayla, Fulda, Evelynne S, Diggs, Marissa R, Bloomfield, Gerald S, Malvestutto, Carlos D, Fichtenbaum, Carl J, Aberg, Judith A, Currier, Judith S, Ribaudo, Heather J, Hoffmann, Udo, and Lu, Michael T
- Subjects
- *
CORONARY arterial radiography , *HIV infection complications , *HEART disease risk factors , *HIV-positive persons , *BIOMARKERS , *CONFIDENCE intervals , *INFLAMMATION , *PATHOLOGICAL anatomy , *CORONARY angiography , *RISK assessment , *COMPARATIVE studies , *CORONARY artery disease , *DESCRIPTIVE statistics , *RESEARCH funding , *LOGISTIC regression analysis , *COMPUTED tomography , *ODDS ratio , *LONGITUDINAL method , *DISEASE complications - Abstract
Background Pericoronary adipose tissue (PCAT) may influence plaque development through inflammatory mechanisms. We assessed PCAT density, as a measure of pericoronary inflammation, in relationship to coronary plaque among people with human immunodeficiency virus (HIV [PWH]) and to a matched control population. Methods In this baseline analysis of 727 participants of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) Mechanistic Substudy, we related computed tomography–derived PCAT density to presence and extent (Leaman score) of coronary artery disease (CAD), noncalcified plaque, coronary artery calcium (CAC), and vulnerable plaque features using multivariable logistic regression analyses. We further compared the PCAT density between PWH and age, sex, body mass index, CAC score, and statin use–matched controls from the community-based Framingham Heart Study (N = 464), adjusting for relevant clinical covariates. Results Among 727 REPRIEVE participants (age 50.8 ± 5.8 years; 83.6% [608/727] male), PCAT density was higher in those with (vs without) coronary plaque, noncalcified plaque, CAC >0, vulnerable plaque, and high CAD burden (Leaman score >5) (P <.001 for each comparison). PCAT density related to prevalent coronary plaque (adjusted odds ratio [per 10 HU]: 1.44; 95% confidence interval, 1.22–1.70; P <.001), adjusted for clinical cardiovascular risk factors, body mass index, and systemic immune/inflammatory biomarkers. Similarly, PCAT density related to CAC >0, noncalcified plaque, vulnerable plaque, and Leaman score >5 (all P ≤.002). PCAT density was greater among REPRIEVE participants versus Framingham Heart Study (−88.2 ± 0.5 HU versus −90.6 ± 0.4 HU; P <.001). Conclusions Among PWH in REPRIEVE, a large primary cardiovascular disease prevention cohort, increased PCAT density independently associated with prevalence and severity of coronary plaque, linking increased coronary inflammation to CAD in PWH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Metabolomic profiling of preterm birth in pregnant women living with HIV.
- Author
-
Tobin, Nicole H., Murphy, Aisling, Li, Fan, Brummel, Sean S., Fowler, Mary Glenn, Mcintyre, James A., Currier, Judith S., Chipato, Tsungai, Flynn, Patricia M., Gadama, Luis A., Saidi, Friday, Nakabiito, Clemensia, Koos, Brian J., and Aldrovandi, Grace M.
- Subjects
- *
PREMATURE labor , *HIV-positive women , *PREGNANT women , *RESOURCE-limited settings , *CHILD mortality , *HIV infections - Abstract
Background: Preterm birth is a leading cause of death in children under the age of five. The risk of preterm birth is increased by maternal HIV infection as well as by certain antiretroviral regimens, leading to a disproportionate burden on low- and medium-income settings where HIV is most prevalent. Despite decades of research, the mechanisms underlying spontaneous preterm birth, particularly in resource limited areas with high HIV infection rates, are still poorly understood and accurate prediction and therapeutic intervention remain elusive. Objectives: Metabolomics was utilized to identify profiles of preterm birth among pregnant women living with HIV on two different antiretroviral therapy (ART) regimens. Methods: This pilot study comprised 100 mother-infant dyads prior to antiretroviral initiation, on zidovudine monotherapy or on protease inhibitor-based antiretroviral therapy. Pregnancies that resulted in preterm births were matched 1:1 with controls by gestational age at time of sample collection. Maternal plasma and blood spots at 23–35 weeks gestation and infant dried blood spots at birth, were assayed using an untargeted metabolomics method. Linear regression and random forests classification models were used to identify shared and treatment-specific markers of preterm birth. Results: Classification models for preterm birth achieved accuracies of 95.5%, 95.7%, and 80.7% in the untreated, zidovudine monotherapy, and protease inhibitor-based treatment groups, respectively. Urate, methionine sulfone, cortisone, and 17α-hydroxypregnanolone glucuronide were identified as shared markers of preterm birth. Other compounds including hippurate and N-acetyl-1-methylhistidine were found to be significantly altered in a treatment-specific context. Conclusion: This study identified previously known as well as novel metabolomic features of preterm birth in pregnant women living with HIV. Validation of these models in a larger, independent cohort is necessary to ascertain whether they can be utilized to predict preterm birth during a stage of gestation that allows for therapeutic intervention or more effective resource allocation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
- Author
-
Jilg, Nikolaus, Chew, Kara W, Giganti, Mark J, Daar, Eric S, Wohl, David A, Javan, Arzhang Cyrus, Kantor, Amy, Moser, Carlee, Coombs, Robert W, Neytman, Gene, Hoover, Keila, Jana, Atasi, Hart, Phil A, Greninger, Alexander L, Szurgot, Bob, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Smith, Davey M, and Li, Jonathan Z
- Subjects
- *
THERAPEUTIC use of protease inhibitors , *DRUG efficacy , *COVID-19 , *PROTEASE inhibitors , *ORAL drug administration , *RANDOMIZED controlled trials , *DESCRIPTIVE statistics , *RESEARCH funding , *STATISTICAL sampling , *PATIENT safety , *ADULTS - Abstract
Background Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a phase 2/3 platform trial of therapeutics for COVID-19 in nonhospitalized adults. Methods We conducted a phase 2 study in adults with mild-to-moderate COVID-19 randomized to oral camostat for 7 days or a pooled placebo arm. Primary outcomes were time to improvement in COVID-19 symptoms through day 28, proportion of participants with SARS-CoV-2 RNA below the lower limit of quantification (LLoQ) from nasopharyngeal swabs through day 14, and grade ≥3 treatment-emergent adverse events (TEAEs) through day 28. Results Of 216 participants (109 randomized to camostat, 107 to placebo) who initiated study intervention, 45% reported ≤5 days of symptoms at study entry and 26% met the protocol definition of higher risk of progression to severe COVID-19. Median age was 37 years. Median time to symptom improvement was 9 days in both arms (P =.99). There were no significant differences in the proportion of participants with SARS-CoV-2 RNA
- Published
- 2023
- Full Text
- View/download PDF
30. Risk of myocardial infarction and nucleoside analogues.
- Author
-
Stein, James H. and Currier, Judith S.
- Subjects
- *
NUCLEOSIDES , *REVERSE transcriptase , *MYOCARDIAL infarction risk factors , *HIV-positive persons , *DRUG side effects - Abstract
The author comments on a study published within the issue that seeks to determine whether a group of nucleoside reverse transcriptase inhibitors increase the risk of myocardial infarction among HIV patients. The different outcomes for the drugs abacavir and didanosine compared to zidovudine and stavudine are weighted. The clinical implications of the findings are discussed.
- Published
- 2008
- Full Text
- View/download PDF
31. Sex Differences in Antiretroviral Therapy Toxicity: Lactic Acidosis, Stavudine, and Women.
- Author
-
Currier, Judith S.
- Subjects
- *
ACIDOSIS , *ANTIVIRAL agents , *ACID-base imbalances - Abstract
The article presents the author's comments on the article "A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa," by M.G. Bolhaar and colleagues published in this issue. According to the author, the urgency of ongoing efforts to secure lower-cost alternative first-line treatment regimens to replace stavudine is underscored by the data reported by Bolhaar and colleagues in their article.
- Published
- 2007
- Full Text
- View/download PDF
32. Introduction.
- Author
-
Currier, Judith S.
- Subjects
- *
AIDS , *RETROVIRUS disease treatment , *ATHEROSCLEROSIS , *CORONARY disease - Abstract
Presents a series of articles published in the September 1, 2002 supplement issue of the 'Journal of Acquired Immune Deficiency Syndromes.' Toxicities associated with highly active antiretroviral therapy (HAART); Use of HAART in HIV treatment; Impact of HIV infection on accelerated atherosclerosis and coronary heart disease.
- Published
- 2002
- Full Text
- View/download PDF
33. Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials.
- Author
-
Huaman, Moises A., Raval, Jay S., Paxton, James H., Mosnaim, Giselle S., Patel, Bela, Anjan, Shweta, Meisenberg, Barry R., Levine, Adam C., Marshall, Christi E., Yarava, Anusha, Shenoy, Aarthi G., Heath, Sonya L., Currier, Judith S., Fukuta, Yuriko, Blair, Janis E., Spivak, Emily S., Petrini, Joann R., Broderick, Patrick B., Rausch, William, and Cordisco, MarieElena
- Subjects
- *
CONVALESCENT plasma , *COVID-19 , *CLINICAL trials , *BLOOD platelet transfusion , *OUTPATIENTS , *PLASMA confinement - Abstract
Background: COVID‐19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials. Study Design and Methods: We analyzed data pertaining to transfusion‐related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders. Results: The combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 (4.6%) characterized by mild, allergic‐type findings of urticaria, and/or pruritus consistent with minor allergic transfusion reactions; the other reported events were attributed to the patients' underlying disease, COVID‐19, or vasovagal in nature. We found no difference in the likelihood of allergic transfusion reactions between those receiving CCP versus control plasma (adjusted odds ratio [AOR], 0.75; 95% CI, 0.43–1.31). Risk of urticaria and/or pruritus increased with a pre‐existing diagnosis of asthma (AOR, 2.33; 95% CI, 1.16–4.67). We did not observe any CCP‐attributed antibody disease enhancement in participants with COVID‐19 or increased risk of infection. There were no life‐threatening severe transfusion reactions and no patients required hospitalization related to transfusion‐associated complications. Discussion: Outpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID‐19. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Variant-Specific Viral Kinetics in Acute COVID-19.
- Author
-
Ribeiro, Ruy M, Choudhary, Manish C, Deo, Rinki, Giganti, Mark J, Moser, Carlee, Ritz, Justin, Greninger, Alexander L, Regan, James, Flynn, James P, Wohl, David A, Currier, Judith S, Eron, Joseph J, Hughes, Michael D, Smith, Davey M, Chew, Kara W, Daar, Eric S, Perelson, Alan S, Li, Jonathan Z, and Team, for the ACTIV-2/A5401 Study
- Subjects
- *
SARS-CoV-2 , *SARS-CoV-2 Delta variant , *CLINICAL trial registries , *COVID-19 - Abstract
Understanding variant-specific differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral kinetics may explain differences in transmission efficiency and provide insights on pathogenesis and prevention. We evaluated SARS-CoV-2 kinetics from nasal swabs across multiple variants (Alpha, Delta, Epsilon, Gamma) in placebo recipients of the ACTIV-2/A5401 trial. Delta variant infection led to the highest maximum viral load and shortest time from symptom onset to viral load peak. There were no significant differences in time to viral clearance across the variants. Viral decline was biphasic with first- and second-phase decays having half-lives of 11 hours and 2.5 days, respectively, with differences among variants, especially in the second phase. These results suggest that while variant-specific differences in viral kinetics exist, post–peak viral load all variants appeared to be efficiently cleared by the host. Clinical Trials Registration. NCT04518410. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
- Author
-
Giganti, Mark J, Chew, Kara W, Eron, Joseph J, Li, Jonathan Z, Pinilla, Mauricio, Moser, Carlee, Javan, Arzhang Cyrus, Fischer, William A, Klekotka, Paul, Margolis, David, Wohl, David Alain, Coombs, Robert W, Daar, Eric S, Smith, Davey M, Currier, Judith S, Hughes, Michael D, and Team, for the ACTIV-2/A5401 Study
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *CLINICAL trial registries - Abstract
Background There is little information regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA as a predictor for clinical outcomes in outpatients with mild-to-moderate coronavirus disease 2019 (COVID-19). Methods Anterior nasal (AN) and plasma SARS-CoV-2 RNA data from 2115 nonhospitalized adults who received monoclonal antibodies (mAbs) or placebo in the ACTIV-2/A5401 trial were analyzed for associations with hospitalization or death. Results One hundred two participants were hospitalized or died through 28 days of follow-up. Higher day 0 (pretreatment) AN RNA was associated with increasing risk of hospitalization/death (risk ratio [RR], 1.24 per log10 copies/mL [95% confidence interval {CI}, 1.04–1.49]) among placebo recipients, ranging from 3% to 16% for <2 to ≥6 log10 copies/mL. Although only 1% had quantifiable levels, there was a similar trend across day 0 plasma RNA categories. Higher day 3 AN RNA was associated with subsequent hospitalization/death among placebo recipients (RR, 1.42 per log10 copies/mL [95% CI, 1.00–2.03]), but not mAb recipients (RR, 1.02 per log10 copies/mL [95% CI, 0.68–1.56]). The proportion of treatment effect (reduction in hospitalizations/deaths after day 3 for mAb vs placebo) explained by day 3 AN RNA was 8%. Conclusions SARS-CoV-2 RNA levels are predictive of hospitalization/death in the natural history setting, but AN RNA levels may not be a reliable surrogate marker of mAb treatment effect in COVID-19 trials. Clinical Trials Registration. NCT04518410. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Long COVID After Bamlanivimab Treatment.
- Author
-
Evering, Teresa H, Moser, Carlee B, Jilg, Nikolaus, Yeh, Eunice, Sanusi, Busola, Wohl, David A, Daar, Eric S, Li, Jonathan Z, Klekotka, Paul, Javan, Arzhang Cyrus, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Smith, Davey M, Chew, Kara W, and Team, for the ACTIV-2/A5401 Study
- Subjects
- *
POST-acute COVID-19 syndrome , *SARS-CoV-2 , *COVID-19 , *CLINICAL trial registries - Abstract
Background Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab in ACTIV-2/A5401. Methods Data were analyzed from participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021. Long COVID was defined as the presence of self-assessed COVID symptoms at week 24. Self-assessed return to pre-COVID health was also examined. Associations were assessed by regression models. Results Among 506 participants, median age was 51 years. Half were female, 5% Black/African American, and 36% Hispanic/Latino. At 24 weeks, 18% reported long COVID and 15% had not returned to pre-COVID health. Smoking (adjusted risk ratio [aRR], 2.41 [95% confidence interval {CI}, 1.34– 4.32]), female sex (aRR, 1.91 [95% CI, 1.28–2.85]), non-Hispanic ethnicity (aRR, 1.92 [95% CI, 1.19–3.13]), and presence of symptoms 22–28 days posttreatment (aRR, 2.70 [95% CI, 1.63–4.46]) were associated with long COVID, but nasal severe acute respiratory syndrome coronavirus 2 RNA was not. Conclusions Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22–28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention. Clinical Trials Registration NCT04518410. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
- Author
-
Moser, Carlee B, Chew, Kara W, Giganti, Mark J, Li, Jonathan Z, Aga, Evgenia, Ritz, Justin, Greninger, Alexander L, Javan, Arzhang Cyrus, Ignacio, Rachel Bender, Daar, Eric S, Wohl, David A, Currier, Judith S, Eron, Joseph J, Smith, Davey M, Hughes, Michael D, and Team, for the ACTIV-2/A5401 Study
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *CLINICAL trial registries - Abstract
Most clinical trials evaluating coronavirus disease 2019 (COVID-19) therapeutics include assessments of antiviral activity. In recently completed outpatient trials, changes in nasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA levels from baseline were commonly assessed using analysis of covariance (ANCOVA) or mixed models for repeated measures (MMRM) with single imputation for results below assay lower limits of quantification (LLoQ). Analyzing changes in viral RNA levels with singly imputed values can lead to biased estimates of treatment effects. In this article, using an illustrative example from the ACTIV-2 trial, we highlight potential pitfalls of imputation when using ANCOVA or MMRM methods, and illustrate how these methods can be used when considering values
- Published
- 2023
- Full Text
- View/download PDF
38. Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.
- Author
-
Chew, Kara W, Moser, Carlee, Yeh, Eunice, Wohl, David A, Daar, Eric S, Ritz, Justin, Javan, Arzhang Cyrus, Eron, Joseph J, Currier, Judith S, Smith, Davey M, Hughes, Michael D, and Team, for the ACTIV-2/A5401 Study
- Subjects
- *
COVID-19 treatment , *CLINICAL trial registries , *COVID-19 , *SYMPTOMS - Abstract
Background Time to symptom resolution measures were used in outpatient coronavirus disease 2019 (COVID-19) treatment trials without prior validation. Methods ACTIV-2/A5401 trial participants completed a COVID-19 diary assessing 13 targeted symptoms and global experience (overall COVID-19 symptoms, return to pre–COVID-19 health) daily for 29 days. We evaluated concordance of time to sustained (2 days) resolution of all targeted symptoms (TSR) with resolution of overall symptoms and return to health in participants receiving placebo. Results The analysis included 77 high-risk and 81 standard-risk participants with overall median 6 days of symptoms at entry and median age 47 years, 50% female, 82% white, and 31% Hispanic/Latino. Correlation between TSR and resolution of overall symptoms was 0.80 and 0.68, and TSR and return to health, 0.66 and 0.57 for high- and standard-risk groups, respectively. Of the high- and standard-risk participants, 61% and 79%, respectively, achieved targeted symptom resolution, of which 47% and 43%, respectively, reported symptom recurrence. Requiring >2 days to define sustained resolution reduced the frequency of recurrences. Conclusions There was good internal consistency between TSR and COVID-19–specific global outcomes, supporting TSR as a trial end point. Requiring >2 days of symptom resolution better addresses natural symptom fluctuations but must be balanced against the potential influence of non-COVID-19 symptoms. Clinical Trials Registration NCT04518410. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
- Author
-
Moser, Carlee B, Chew, Kara W, Ritz, Justin, Newell, Matthew, Javan, Arzhang Cyrus, Eron, Joseph J, Daar, Eric S, Wohl, David A, Currier, Judith S, Smith, Davey M, Hughes, Michael D, and Team, for the ACTIV-2/A5401 Study
- Subjects
- *
CLINICAL trial registries , *PLACEBOS , *COVID-19 , *CONTROL groups , *TREATMENT effectiveness - Abstract
Adaptive platform trials were implemented during the coronavirus disease 2019 (COVID-19) pandemic to rapidly evaluate therapeutics, including the placebo-controlled phase 2/3 ACTIV-2 trial, which studied 7 investigational agents with diverse routes of administration. For each agent, safety and efficacy outcomes were compared to a pooled placebo control group, which included participants who received a placebo for that agent or for other agents in concurrent evaluation. A 2-step randomization framework was implemented to facilitate this. Over the study duration, the pooled placebo design achieved a reduction in sample size of 6% versus a trial involving distinct placebo control groups for evaluating each agent. However, a 26% reduction was achieved during the period when multiple agents were in parallel phase 2 evaluation. We discuss some of the complexities implementing the pooled placebo design versus a design involving nonoverlapping control groups, with the aim of informing the design of future platform trials. Clinical Trials Registration. NCT04518410. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Immune Status and SARS-CoV-2 Viral Dynamics.
- Author
-
Li, Yijia, Moser, Carlee, Aga, Evgenia, Currier, Judith S, Wohl, David A, Daar, Eric S, Ritz, Justin, Greninger, Alexander L, Sieg, Scott, Parikh, Urvi M, Coombs, Robert W, Hughes, Michael D, Eron, Joseph J, Smith, Davey M, Chew, Kara W, Li, Jonathan Z, and Team, for the ACTIV-2/A5401 Study
- Subjects
- *
SARS-CoV-2 , *IMMUNITY , *COVID-19 , *CLINICAL trial registries - Abstract
Immunocompromised individuals are disproportionately affected by severe coronavirus disease 2019, but immune compromise is heterogenous, and viral dynamics may vary by the degree of immunosuppression. In this study, we categorized ACTIV-2/A5401 participants based on the extent of immunocompromise into none, mild, moderate, and severe immunocompromise. Moderate/severe immunocompromise was associated with higher nasal viral load at enrollment (adjusted difference in means: 0.47 95% confidence interval,.12–.83 log10 copies/mL) and showed a trend toward higher cumulative nasal RNA levels and plasma viremia compared to nonimmunocompromised individuals. Immunosuppression leads to greater viral shedding and altered severe acute respiratory syndrome coronavirus 2 viral decay kinetics. Clinical Trials Registration. NCT04518410. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus: A Randomized Controlled Trial.
- Author
-
Bhattacharya, Debika, Tierney, Camlin, Butler, Kevin, Kiweewa, Flavia Matovu, Moodley, Dhayendre, Govender, Vani, Vhembo, Tichaona, Mohtashemi, Neaka, Ship, Hannah, Dula, Dingase, George, Kathy, Chaktoura, Nahida, Fowler, Mary Glenn, Peters, Marion G., and Currier, Judith S.
- Subjects
- *
HIV , *HEPATITIS B virus , *PREGNANT women , *RANDOMIZED controlled trials , *ANTIRETROVIRAL agents - Abstract
OBJECTIVE: To describe the anti--hepatitis B virus (HBV) efficacy, HBeAg serologic changes, HBV perinatal transmission, and safety in pregnant women who are living with human immunodeficiency virus (HIV) and HBV coinfection who were randomized to various antiretroviral therapy (ART) regimens. METHODS: The PROMISE (Promoting Maternal and Infant Survival Everywhere) trial was a multicenter randomized trial for ART-naive pregnant women with HIV infection. Women with HIV and HBV co-infection at 14 or more weeks of gestation were randomized to one of three ART arms: one without HBV treatment (group 1) and two HBV treatment arms with single (group 2) or dual anti-HBV activity (group 3). The primary HBV outcome was HBV viral load antepartum change from baseline (enrollment) to 8 weeks; safety assessments included alanine aminotransferase (ALT) level, aspartate aminotransferase (AST) level, and anemia (hemoglobin less than 10 g/dL). Primary comparison was for the HBV-active treatment arms. Pairwise comparisons applied t test and the Fisher exact tests. RESULTS: Of 3,543 women, 3.9% were HBsAg-positive; 42 were randomized to group 1, 48 to group 2, and 48 to group 3. Median gestational age at enrollment was 27 weeks. Among HBV-viremic women, mean antepartum HBV viral load change at week 8 was 20.26 log10 international units/mL in group 1, 21.86 in group 2, and 21.89 in group 3. In those who were HBeAg-positive, HBeAg loss occurred in 44.4% at delivery. Two perinatal HBV transmissions occurred in group 2. During the antepartum period, one woman (2.4%) in group 1 had grade 3 or 4 ALT or AST elevations, two women (4.2%) in group 2, and three women (6.3%) in group 3. CONCLUSION: Over a short period of time, HBV DNA suppression was not different with one or two HBV-active agents. HbeAg loss occurred in a substantial proportion of participants. Perinatal transmission of HBV infection was low. Hepatitis B virus--active ART was well-tolerated in pregnancy, with few grade 3 or 4 ALT or AST elevations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.
- Author
-
Grinspoon, Steven K., Fitch, Kathleen V., Zanni, Markella V., Fichtenbaum, Carl J., Umbleja, Triin, Aberg, Judith A., Overton, Edgar T., Malvestutto, Carlos D., Bloomfield, Gerald S., Currier, Judith S., Martinez, Esteban, Roa, Jhoanna C., Diggs, Marissa R., Fulda, Evelynne S., Paradis, Kayla, Wiviott, Stephen D., Foldyna, Borek, Looby, Sara E., Desvigne-Nickens, Patrice, and Alston-Smith, Beverly
- Abstract
BACKGROUND The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV) infection, so data regarding primary prevention strategies in this population are needed. METHODS In this phase 3 trial, we randomly assigned 7769 participants with HIV infection with a low-to-moderate risk of cardiovascular disease who were receiving antiretroviral therapy to receive daily pitavastatin calcium (at a dose of 4 mg) or placebo. The primary outcome was the occurrence of a major adverse cardiovascular event, which was defined as a composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack, peripheral arterial ischemia, revascularization, or death from an undetermined cause. RESULTS The median age of the participants was 50 years (interquartile range, 45 to 55); the median CD4 count was 621 cells per cubic millimeter (interquartile range, 448 to 827), and the HIV RNA value was below quantification in 5250 of 5997 participants (87.5%) with available data. The trial was stopped early for efficacy after a median follow-up of 5.1 years (interquartile range, 4.3 to 5.9). The incidence of a major adverse cardiovascular event was 4.81 per 1000 person-years in the pitavastatin group and 7.32 per 1000 person-years in the placebo group (hazard ratio, 0.65; 95% confidence interval [CI], 0.48 to 0.90; P=0.002). Muscle-related symptoms occurred in 91 participants (2.3%) in the pitavastatin group and in 53 (1.4%) in the placebo group; diabetes mellitus occurred in 206 participants (5.3%) and in 155 (4.0%), respectively. CONCLUSIONS Participants with HIV infection who received pitavastatin had a lower risk of a major adverse cardiovascular event than those who received placebo over a median follow-up of 5.1 years. (Funded by the National Institutes of Health and others; REPRIEVE ClinicalTrials.gov number, NCT02344290.) [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
- Author
-
Taiwo, Babafemi O, Chew, Kara W, Moser, Carlee, Wohl, David Alain, Daar, Eric S, Li, Jonathan Z, Greninger, Alexander L, Bausch, Christoph, Luke, Thomas, Hoover, Keila, Neytman, Gene, Giganti, Mark J, Olefsky, Maxine, Javan, Arzhang Cyrus, Fletcher, Courtney V, Eron, Joseph J, Currier, Judith S, Hughes, Michael D, Smith, Davey M, and Team, for the ACTIV-2/A5401 Study
- Subjects
- *
SARS-CoV-2 , *CORONAVIRUS diseases , *COVID-19 , *CLINICAL trial registries , *IMMUNOGLOBULIN G - Abstract
Background SAB-185, a novel fully human IgG polyclonal immunoglobulin product, underwent phase 2 evaluation for nonhospitalized adults with mild-moderate coronavirus disease 2019 (COVID-19). Methods Participants received intravenous SAB-185 3840 units/kg (low-dose) or placebo, or 10 240 units/kg (high-dose) or placebo. Primary outcome measures were nasopharyngeal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA < lower limit of quantification (LLOQ) at study days 3, 7, and 14, time to symptomatic improvement, and safety through day 28. Results Two-hundred thirteen participants received low-dose SAB-185/placebo (n = 107/106) and 215 high-dose SAB-185/placebo (n = 110/105). The proportions with SARS-CoV-2 RNA < LLOQ were higher for SAB-185 versus placebo at days 3 and 7 and similar at day 14, and significantly higher at day 7 for high-dose SAB-185 versus placebo only, relative risk 1.23 (95% confidence interval, 1.01–1.49). At day 3, SARS-CoV-2 RNA levels were lower with low-dose and high-dose SAB-185 versus placebo: differences in medians of −0.78 log10 copies/mL (P =.08) and −0.71 log10 copies/mL (P =.10), respectively. No difference was observed in time to symptom improvement: median 11/10 days (P =.24) for low-dose SAB-185/placebo and 8/10 days (P =.50) for high-dose SAB-185/placebo. Grade ≥3 adverse events occurred in 5%/13% of low-dose SAB-185/placebo and 9%/12% of high-dose SAB-185/placebo. Conclusions SAB-185 was safe and generally well tolerated and demonstrated modest antiviral activity in predominantly low-risk nonhospitalized adults with COVID-19. Clinical Trials Registration. NCT04518410. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
- Author
-
Evering, Teresa H., Chew, Kara W., Giganti, Mark J., Moser, Carlee, Pinilla, Mauricio, Wohl, David Alain, Currier, Judith S., Eron, Joseph J., Javan, Arzhang Cyrus, Bender Ignacio, Rachel, Margolis, David, Zhu, Qing, Ma, Ji, Zhong, Lijie, Yan, Li, D'Andrea Nores, Ulises, Hoover, Keila, Mocherla, Bharat, Choudhary, Manish C., and Deo, Rinki
- Subjects
- *
COVID-19 , *SARS-CoV-2 Omicron variant , *SARS-CoV-2 , *MONOCLONAL antibodies , *NEUTRALIZATION tests , *COMMUNICABLE diseases - Abstract
This randomized, placebo-controlled trial aimed to determine the overall efficacy and safety of combination therapy with 2 SARS-CoV-2 neutralizing antibodies—amubarvimab and romlusevimab—and evaluated whether there was a benefit of administration more than 5 days after symptom onset. Visual Abstract. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19: This randomized, placebo-controlled trial aimed to determine the overall efficacy and safety of combination therapy with 2 SARS-CoV-2 neutralizing antibodies—amubarvimab and romlusevimab—and evaluated whether there was a benefit of administration more than 5 days after symptom onset. Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal antibodies with an extended half-life. Objective: To assess the safety and efficacy of amubarvimab plus romlusevimab. Design: Randomized, placebo-controlled, phase 2 and 3 platform trial. (ClinicalTrials.gov: NCT04518410) Setting: Nonhospitalized patients with COVID-19 in the United States, Brazil, South Africa, Mexico, Argentina, and the Philippines. Patients: Adults within 10 days onset of symptomatic SARS-CoV-2 infection who are at high risk for clinical progression. Intervention: Combination of monoclonal antibodies amubarvimab plus romlusevimab or placebo. Measurements: Nasopharyngeal and anterior nasal swabs for SARS-CoV-2, COVID-19 symptoms, safety, and progression to hospitalization or death. Results: Eight-hundred and seven participants who initiated the study intervention were included in the phase 3 analysis. Median age was 49 years (quartiles, 39 to 58); 51% were female, 18% were Black, and 50% were Hispanic or Latino. Median time from symptom onset at study entry was 6 days (quartiles, 4 to 7). Hospitalizations and/or death occurred in 9 (2.3%) participants in the amubarvimab plus romlusevimab group compared with 44 (10.7%) in the placebo group, with an estimated 79% reduction in events (P < 0.001). This reduction was similar between participants with 5 or less and more than 5 days of symptoms at study entry. Grade 3 or higher treatment-emergent adverse events through day 28 were seen less frequently among participants randomly assigned to amubarvimab plus romlusevimab (7.3%) than placebo (16.1%) (P < 0.001), with no severe infusion reactions or drug-related serious adverse events. Limitation: The study population was mostly unvaccinated against COVID-19 and enrolled before the spread of Omicron variants and subvariants. Conclusion: Amubarvimab plus romlusevimab was safe and significantly reduced the risk for hospitalization and/or death among nonhospitalized adults with mild to moderate SARS-CoV-2 infection at high risk for progression to severe disease. Primary Funding Source: National Institute of Allergy and Infectious Diseases of the National Institutes of Health. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People With Treated Human Immunodeficiency Virus.
- Author
-
Schnittman, Samuel R, Kitch, Douglas W, Swartz, Talia H, Burdo, Tricia H, Fitch, Kathleen V, McCallum, Sara, Flynn, Jacqueline M, Fulda, Evelynne S, Diggs, Marissa R, Stapleton, Jack T, Casado, José L, Taron, Jana, Currier, Judith S, Zanni, Markella V, Malvestutto, Carlos, Fichtenbaum, Carl J, Aberg, Judith A, Ribaudo, Heather J, Lu, Michael T, and Douglas, Pamela S
- Abstract
Background Inflammasome activation is increased in people with human immunodeficiency virus (PWH), but its relationship with coronary plaque is poorly understood in this setting. Methods In a large human immunodeficiency virus cardiovascular prevention cohort, relationships between caspase-1, interleukin (IL)-1β, and IL-18 and coronary plaque indices were assessed by multivariate logistic regression. Results Higher IL-18 and IL-1β were associated with Leaman score, an integrative measure of plaque burden and composition. Conclusions As Leaman score >5 is associated with cardiovascular events in the general population, future work is needed to determine how the inflammasome relates to events and whether strategies to reduce its activation affect events or plaque progression among PWH. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
- Author
-
Deo, Rinki, Choudhary, Manish C., Moser, Carlee, Ritz, Justin, Daar, Eric S., Wohl, David A., Greninger, Alexander L., Eron, Joseph J., Currier, Judith S., Hughes, Michael D., Smith, Davey M., Chew, Kara W., Li, Jonathan Z., Javan, Arzhang Cyrus, Giganti, Mark, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, and Rwakazina, Irene
- Subjects
- *
SARS-CoV-2 , *COVID-19 treatment , *SYMPTOMS , *VIRAL load , *COMMUNICABLE diseases , *BK virus - Abstract
There have been reports of rebound of SARS-CoV-2 virus and symptoms after receipt of nirmatrelvir–ritonavir for treatment of COVID-19. Using prospectively obtained data from patients receiving placebo in a large COVID-19 "platform" trial, the authors studied the natural history of rebound in the absence of antiviral therapy. Visual Abstract. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.: There have been reports of rebound of SARS-CoV-2 virus and symptoms after receipt of nirmatrelvir–ritonavir for treatment of COVID-19. Using prospectively obtained data from patients receiving placebo in a large COVID-19 "platform" trial, the authors studied the natural history of rebound in the absence of antiviral therapy. Background: Although symptom and viral rebound have been reported after nirmatrelvir–ritonavir treatment, the trajectories of symptoms and viral load during the natural course of COVID-19 have not been well described. Objective: To characterize symptom and viral rebound in untreated outpatients with mild to moderate COVID-19. Design: Retrospective analysis of participants in a randomized, placebo-controlled trial. (ClinicalTrials.gov: NCT04518410) Setting: Multicenter trial. Patients: 563 participants receiving placebo in the ACTIV-2/A5401 (Adaptive Platform Treatment Trial for Outpatients With COVID-19) platform trial. Measurements: Participants recorded the severity of 13 symptoms daily between days 0 and 28. Nasal swabs were collected for SARS-CoV-2 RNA testing on days 0 to 14, 21, and 28. Symptom rebound was defined as a 4-point increase in total symptom score after improvement any time after study entry. Viral rebound was defined as an increase of at least 0.5 log 10 RNA copies/mL from the immediately preceding time point to a viral load of 3.0 log 10 copies/mL or higher. High-level viral rebound was defined as an increase of at least 0.5 log 10 RNA copies/mL to a viral load of 5.0 log 10 copies/mL or higher. Results: Symptom rebound was identified in 26% of participants at a median of 11 days after initial symptom onset. Viral rebound was detected in 31% and high-level viral rebound in 13% of participants. Most symptom and viral rebound events were transient, because 89% of symptom rebound and 95% of viral rebound events occurred at only a single time point before improving. The combination of symptom and high-level viral rebound was observed in 3% of participants. Limitation: A largely unvaccinated population infected with pre-Omicron variants was evaluated. Conclusion: Symptom or viral relapse in the absence of antiviral treatment is common, but the combination of symptom and viral rebound is rare. Primary Funding Source: National Institute of Allergy and Infectious Diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Experiences with telemedicine for HIV care in two federally qualified health centers in Los Angeles: a qualitative study.
- Author
-
Walker, Daisy, Moucheraud, Corrina, Butler, Derrick, de Vente, Jerome, Tangonan, Kevin, Shoptaw, Steven, Currier, Judith S., Gladstein, Jay, and Hoffman, Risa
- Subjects
- *
MEDICAL centers , *TELEMEDICINE , *HIV , *TECHNOLOGICAL literacy , *COVID-19 pandemic , *MEDICAL telematics - Abstract
Background: The SARS-CoV-2 pandemic has resulted in an increase in telemedicine utilization for routine HIV care. However, there is limited information on perceptions of and experiences with telemedicine from United States (U.S.) federally qualified health centers (FQHCs) offering HIV care. We sought to understand telemedicine experiences of stakeholders with various roles: people living with HIV (PLHIV), clinical (clinicians and case managers), programmatic (clinic administrators), and policy (policymakers). Methods: Qualitative interviews about benefits and challenges of telemedicine (telephone and video) for HIV care were conducted with 31 PLHIV and 23 other stakeholders (clinicians, case managers, clinic administrators, and policymakers). Interviews were transcribed, translated to English if conducted in Spanish, coded, and analyzed for major themes. Results: Almost all PLHIV felt capable of engaging in telephone visits, with some expressing interest in learning how to use video visits as well. Nearly all PLHIV wanted to continue telemedicine as part of their routine HIV care, and this was also endorsed by clinical, programmatic and policy stakeholders. Interviewees agreed that telemedicine for HIV care has benefits for PLHIV, especially savings of time and transportation costs, which also reduced stress. Clinical, programmatic, and policy stakeholders expressed concerns around patients' technological literacy and resources, as well as their access to privacy, and some felt that PLHIV strongly preferred in-person visits. These stakeholders also commonly reported clinic-level implementation challenges, including integrating telephone and video telemedicine into workflows and difficulty with video visit platforms. Conclusions: Telemedicine for HIV care, largely delivered via telephone (audio-only), was highly acceptable and feasible for both PLHIV, clinicians, and other stakeholders. Addressing barriers for stakeholders in incorporating video visits will be important for the successful implementation of telemedicine with video as part of routine HIV care at FQHCs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States.
- Author
-
Zanni, Markella V, Foldyna, Borek, McCallum, Sara, Burdo, Tricia H, Looby, Sara E, Fitch, Kathleen V, Fulda, Evelynne S, Autissier, Patrick, Bloomfield, Gerald S, Malvestutto, Carlos D, Fichtenbaum, Carl J, Overton, Edgar T, Aberg, Judith A, Erlandson, Kristine M, Campbell, Thomas B, Ellsworth, Grant B, Sheth, Anandi N, Taiwo, Babafemi, Currier, Judith S, and Hoffmann, Udo
- Subjects
- *
HIV-positive persons , *BIOMARKERS , *INTERLEUKINS , *C-reactive protein , *BLOOD vessels , *CONFIDENCE intervals , *INFLAMMATION , *SEX distribution , *CORONARY artery disease , *RESEARCH funding , *IMMUNOPHENOTYPING , *DESCRIPTIVE statistics , *COMPUTED tomography , *FIBRIN fibrinogen degradation products - Abstract
Background Among people with HIV (PWH), sex differences in presentations of atherosclerotic cardiovascular disease (ASCVD) may be influenced by differences in coronary plaque parameters, immune/inflammatory biomarkers, or relationships therein. Methods REPRIEVE, a primary ASCVD prevention trial, enrolled antiretroviral therapy (ART)–treated PWH. At entry, a subset of US participants underwent coronary computed tomography angiography (CTA) and immune phenotyping (n = 755 CTA; n = 725 CTA + immune). We characterized sex differences in coronary plaque and immune/inflammatory biomarkers and compared immune-plaque relationships by sex. Unless noted otherwise, analyses adjust for ASCVD risk score. Results The primary analysis cohort included 631 males and 124 females. ASCVD risk was higher among males (median: 4.9% vs 2.1%), while obesity rates were higher among females (48% vs 21%). Prevalence of any plaque and of plaque with either ≥1 visible noncalcified portion or vulnerable features (NC/V-P) was lower among females overall and controlling for relevant risk factors (RR [95% CI] for any plaque:.67 [.50,.92]; RR for NC/V-P:.71 [.51, 1.00] [adjusted for ASCVD risk score and body mass index]). Females showed higher levels of IL-6, hs-CRP, and D-dimer and lower levels of Lp-PLA2 (P <.001 for all). Higher levels of Lp-PLA2, MCP-1, and oxLDL were associated with higher plaque (P <.02) and NC/V-P prevalence, with no differences by sex. Among females but not males, D-dimer was associated with higher prevalence of NC/V-P (interaction P =.055). Conclusions Among US PWH, females had a lower prevalence of plaque and NC/V-P, as well as differences in key immune/inflammatory biomarkers. Immune-plaque relationships differed by sex for D-dimer but not other tested parameters. Clinical Trial Registration. ClinicalTrials.gov; identifier: NCT0234429 (date of initial registration: 22 January 2015). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Getting Smarter — The Toxicity of Undertreated HIV Infection.
- Author
-
Currier, Judith S. and Baden, Lindsey R.
- Subjects
- *
CLINICAL trials , *HIV , *ANTIRETROVIRAL agents , *THERAPEUTIC complications - Abstract
The author comments on the Strategies for Management of Antiretroviral Therapy (SMART) trial that was carried out to determine whether withholding therapy for long periods would result in human immunodeficiency viruses (HIV)-associated complications. According to the author, the results of the SMART study underscore the benefit of using adequately powered randomized trials to evaluate new treatment strategies in clinical medicine.
- Published
- 2006
- Full Text
- View/download PDF
50. Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19.
- Author
-
Moser, Carlee, Li, Jonathan Z, Eron, Joseph J, Aga, Evgenia, Daar, Eric S, Wohl, David A, Coombs, Robert W, Javan, Arzhang Cyrus, Ignacio, Rachel A Bender, Jagannathan, Prasanna, Ritz, Justin, Sieg, Scott F, Parikh, Urvi M, Hughes, Michael D, Currier, Judith S, Smith, Davey M, Chew, Kara W, and Team, ACTIV-2/A5401 Study
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *RNA - Abstract
Background Identifying characteristics associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA shedding may be useful to understand viral compartmentalization, disease pathogenesis, and risks for viral transmission. Methods Participants were enrolled August 2020 to February 2021 in ACTIV-2/A5401, a placebo-controlled platform trial evaluating investigational therapies for mild-to-moderate coronavirus disease 2019 (COVID-19), and underwent quantitative SARS-CoV-2 RNA testing on nasopharyngeal and anterior nasal swabs, oral wash/saliva, and plasma at entry (day 0, pretreatment) and days 3, 7, 14, and 28. Concordance of RNA levels (copies/mL) across compartments and predictors of nasopharyngeal RNA levels were assessed at entry (n = 537). Predictors of changes over time were evaluated among placebo recipients (n = 265) with censored linear regression models. Results Nasopharyngeal and anterior nasal RNA levels at study entry were highly correlated (r = 0.84); higher levels of both were associated with greater detection of RNA in plasma and oral wash/saliva. Older age, White non-Hispanic race/ethnicity, lower body mass index (BMI), SARS-CoV-2 immunoglobulin G seronegativity, and shorter prior symptom duration were associated with higher nasopharyngeal RNA at entry. In adjusted models, body mass index and race/ethnicity associations were attenuated, but the association with age remained (for every 10 years older, mean nasopharyngeal RNA was 0.27 log10 copies/mL higher; P <.001). Examining longitudinal viral RNA levels among placebo recipients, women had faster declines in nasopharyngeal RNA than men (mean change, −2.0 vs −1.3 log10 copies/mL, entry to day 3; P <.001). Conclusions SARS-CoV-2 RNA shedding was concordant across compartments. Age was strongly associated with viral shedding, and men had slower viral clearance than women, which could explain sex differences in acute COVID-19 outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.